amlodipine has been researched along with Headache in 30 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA." | 9.27 | Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018) |
| "The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation." | 9.20 | A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. ( Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015) |
| " The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy." | 9.15 | Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011) |
| "Eight weeks of treatment with amlodipine adipate produced significant reductions from baseline in blood pressure in these patients with mild to moderate hypertension." | 9.11 | Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison. ( Chong-Yun, R; Heung-Sun, K; Jin-Ok, J; Joo, SJ; Joon-Han, S; Ju, AK; Kang, HJ; Kang, JH; Kim, KS; Kim, MH; Koo, BK; Lee, HY; Lim, DK; Oh, BH; Park, KM; Park, SH; Park, SY; Ro, YM; Seo, HS; Woong, CJ; Yeon, KJ; Yoon, J, 2005) |
| "The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension." | 9.10 | Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. ( Gil-Extremera, B; Maldonato, A; Mazza, A; Pessina, AC; Toutouzas, T, 2002) |
| "Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure." | 9.10 | Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003) |
| "One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks." | 9.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996) |
| "The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension." | 9.08 | -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 9.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "Although risks of peripheral edema are three-fold higher on amlodipine, up to one-third of edema cases on amlodipine might not be induced by amlodipine." | 9.01 | Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. ( Böhm, M; Mahfoud, F; Messerli, FH; Scholz, SS; Vukadinović, D; Weber, MA; Williams, B, 2019) |
| " Both treatment groups had similar adverse event rates (35." | 6.76 | Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. ( Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011) |
| " Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients." | 6.67 | A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. ( Varrone, J, 1991) |
| "This 8-week study in Korea aimed to evaluate the efficacy and tolerability of a telmisartan/amlodipine + hydrochlorothiazide (TAH) combination versus telmisartan/amlodipine (TA) combination in patients with essential hypertension that did not respond appropriately to 4-week treatment with TA." | 5.27 | Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St ( Ahn, JC; Ahn, JH; Ahn, YK; Cha, DH; Chae, IH; Cho, DK; Cho, SK; Choi, YJ; Hong, SJ; Hong, TJ; Hyon, MS; Jang, JY; Jeon, DW; Jeong, JO; Kim, BS; Kim, HS; Kim, SH; Nam, CW; Oh, YS; Park, SH; Rha, SW; Song, JM; Sung, KC; Won, KH; Yang, TH; Yoo, BS; Yoo, KD; Yoon, YW, 2018) |
| "The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation." | 5.20 | A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. ( Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015) |
| " The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy." | 5.15 | Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011) |
| "In these adult patients with mild to moderate hypertension, the combination of amlodipine + valsartan was associated with significantly greater blood pressure reductions from baseline compared with amlodipine or valsartan monotherapy or placebo." | 5.12 | Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten ( Glazer, R; Jin, J; Philipp, T; Pospiech, R; Schneider, H; Smith, TR; Wernsing, M; Yen, J, 2007) |
| "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension." | 5.12 | Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stag ( Bagchi, A; Baliga, VP; Bollmall, C; Kinagi, SB; Sharma, A; Sharma, YK, 2007) |
| "Eight weeks of treatment with amlodipine adipate produced significant reductions from baseline in blood pressure in these patients with mild to moderate hypertension." | 5.11 | Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison. ( Chong-Yun, R; Heung-Sun, K; Jin-Ok, J; Joo, SJ; Joon-Han, S; Ju, AK; Kang, HJ; Kang, JH; Kim, KS; Kim, MH; Koo, BK; Lee, HY; Lim, DK; Oh, BH; Park, KM; Park, SH; Park, SY; Ro, YM; Seo, HS; Woong, CJ; Yeon, KJ; Yoon, J, 2005) |
| "Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure." | 5.10 | Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003) |
| "The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension." | 5.10 | Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. ( Gil-Extremera, B; Maldonato, A; Mazza, A; Pessina, AC; Toutouzas, T, 2002) |
| "The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension." | 5.08 | -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995) |
| "One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks." | 5.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 5.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "In a multicentre crossover study of 97 patients with mild hypertension, the incidence and severity of adverse effects were observed during the first 14 days of treatment with amlodipine, nifedipine retard or placebo." | 5.07 | Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. ( Bremner, AD; Fell, PJ; Hosie, J; James, IG; Saul, PA; Taylor, SH, 1993) |
| "The effects of amlodipine on ambulatory blood pressure were investigated in patients with mild-to-moderate hypertension." | 5.07 | A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure. ( Burris, JF; Klein, J; Mroczek, WJ, 1991) |
| "Although risks of peripheral edema are three-fold higher on amlodipine, up to one-third of edema cases on amlodipine might not be induced by amlodipine." | 5.01 | Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. ( Böhm, M; Mahfoud, F; Messerli, FH; Scholz, SS; Vukadinović, D; Weber, MA; Williams, B, 2019) |
| "the Indonesian subset of the EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks." | 3.81 | Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study. ( Abdillah, A; Kalim, H; Setiawati, A, 2015) |
| " Both treatment groups had similar adverse event rates (35." | 2.76 | Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. ( Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011) |
| "We conducted 3 open-label, multiple-dose, 3-period, randomized, crossover studies in healthy subjects to assess the potential pharmacokinetic interaction between vildagliptin, a novel dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, and representatives of 3 commonly prescribed antihypertensive drug classes: (1) the calcium channel blocker, amlodipine; (2) the angiotensin receptor blocker, valsartan; and (3) the angiotensin-converting enzyme inhibitor, ramipril." | 2.73 | Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. ( Campestrini, J; Dole, K; Dole, WP; He, YL; Howard, D; Ligueros-Saylan, M; Marion, A; Pommier, F; Sabo, R; Sunkara, G; Wang, Y; Zhao, C, 2008) |
| "The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine." | 2.69 | Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. ( Aldons, PM; Burgess, ED; Girerd, X; Morgan, TO; Rehn, L; Schaefer, RM; Singh, GP; Tilvis, R, 1998) |
| " Neither AUC nor trough levels of FEL and AML were significantly influenced by transit times, nor was Cmax after any of the three treatments." | 2.69 | The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times. ( Laufen, H; Riedel, KD; Scharpf, F; Schumacher, T; Yeates, R; Zimmermann, T, 1999) |
| " Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients." | 2.67 | A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. ( Varrone, J, 1991) |
| "Aggressive treatment of hypertension resulted in complete resolution of the clinical and radiologic features of the syndrome." | 1.43 | Does this patient have hypertensive encephalopathy? ( Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (26.67) | 18.2507 |
| 2000's | 9 (30.00) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konan, ML | 1 |
| Tokpa, A | 1 |
| Okamon, M | 1 |
| Wilfried, M | 1 |
| N'gassa, A | 1 |
| Brou, J | 1 |
| Djondé, G | 1 |
| Oka, DN | 1 |
| Roffey, E | 1 |
| Bhurawala, H | 1 |
| Jafari, R | 1 |
| Rostami, Z | 1 |
| Nikpoor, M | 1 |
| Javanbakht, M | 1 |
| Ghahroudi, MS | 1 |
| Hosseini, MS | 1 |
| Einollahi, B | 1 |
| Reid, HW | 1 |
| Moorthy, G | 1 |
| Clark, D | 1 |
| Cannon, L | 1 |
| Ming, DY | 1 |
| Sung, KC | 2 |
| Oh, YS | 1 |
| Cha, DH | 1 |
| Hong, SJ | 1 |
| Won, KH | 1 |
| Yoo, KD | 1 |
| Rha, SW | 1 |
| Ahn, YK | 1 |
| Ahn, JC | 1 |
| Jang, JY | 1 |
| Hong, TJ | 1 |
| Cho, SK | 1 |
| Park, SH | 2 |
| Hyon, MS | 2 |
| Nam, CW | 1 |
| Chae, IH | 1 |
| Yoo, BS | 2 |
| Song, JM | 1 |
| Jeong, JO | 2 |
| Yoon, YW | 1 |
| Kim, BS | 1 |
| Yang, TH | 1 |
| Cho, DK | 1 |
| Kim, SH | 1 |
| Choi, YJ | 1 |
| Ahn, JH | 1 |
| Jeon, DW | 1 |
| Kim, HS | 1 |
| Tsuchida, T | 1 |
| Yano, H | 1 |
| Raita, Y | 1 |
| Kinjo, M | 1 |
| Tafoya, C | 1 |
| Singh, A | 1 |
| Vukadinović, D | 1 |
| Scholz, SS | 1 |
| Messerli, FH | 1 |
| Weber, MA | 2 |
| Williams, B | 1 |
| Böhm, M | 1 |
| Mahfoud, F | 1 |
| Lee, HY | 2 |
| Kim, YJ | 1 |
| Ahn, T | 1 |
| Youn, HJ | 1 |
| Chull Chae, S | 1 |
| Seog Seo, H | 1 |
| Kim, KS | 2 |
| Rhee, MY | 1 |
| Choi, DJ | 1 |
| Kim, JJ | 1 |
| Chun, KJ | 1 |
| Park, JS | 1 |
| Oh, SK | 1 |
| Kim, DS | 1 |
| Kwan, J | 1 |
| Ahn, Y | 1 |
| Bae Park, J | 1 |
| Cho, EJ | 1 |
| Han, KR | 1 |
| Kim, DI | 1 |
| Joo, SJ | 2 |
| Shin, JH | 1 |
| Jeon, ES | 1 |
| Setiawati, A | 1 |
| Kalim, H | 1 |
| Abdillah, A | 1 |
| Christopoulou, F | 1 |
| Rizos, EC | 1 |
| Kosta, P | 1 |
| Argyropoulou, MI | 1 |
| Elisaf, M | 1 |
| Castelino, FV | 1 |
| Wasfy, JH | 1 |
| Collier, D | 1 |
| Ferdinand, KC | 1 |
| Pool, J | 1 |
| Weitzman, R | 1 |
| Purkayastha, D | 2 |
| Townsend, R | 1 |
| Black, HR | 1 |
| Weinberger, MH | 1 |
| Lee, J | 1 |
| Sridharan, K | 1 |
| Israel, M | 1 |
| Hilkert, R | 1 |
| Izzo, J | 1 |
| Mazza, A | 1 |
| Gil-Extremera, B | 1 |
| Maldonato, A | 1 |
| Toutouzas, T | 1 |
| Pessina, AC | 1 |
| White, WB | 1 |
| Duprez, D | 1 |
| St Hillaire, R | 1 |
| Krause, S | 1 |
| Roniker, B | 1 |
| Kuse-Hamilton, J | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Oh, BH | 1 |
| Heung-Sun, K | 1 |
| Seo, HS | 1 |
| Ro, YM | 1 |
| Kang, JH | 1 |
| Woong, CJ | 1 |
| Kim, MH | 1 |
| Joon-Han, S | 1 |
| Yoon, J | 1 |
| Jin-Ok, J | 1 |
| Ju, AK | 1 |
| Chong-Yun, R | 1 |
| Yeon, KJ | 1 |
| Park, KM | 1 |
| Lim, DK | 1 |
| Park, SY | 1 |
| Chung, M | 1 |
| Calcagni, A | 1 |
| Glue, P | 1 |
| Bramson, C | 1 |
| Philipp, T | 1 |
| Smith, TR | 1 |
| Glazer, R | 1 |
| Wernsing, M | 1 |
| Yen, J | 1 |
| Jin, J | 1 |
| Schneider, H | 1 |
| Pospiech, R | 1 |
| He, YL | 1 |
| Ligueros-Saylan, M | 1 |
| Sunkara, G | 1 |
| Sabo, R | 1 |
| Zhao, C | 1 |
| Wang, Y | 1 |
| Campestrini, J | 1 |
| Pommier, F | 1 |
| Dole, K | 1 |
| Marion, A | 1 |
| Dole, WP | 1 |
| Howard, D | 1 |
| Sharma, A | 1 |
| Bagchi, A | 1 |
| Kinagi, SB | 1 |
| Sharma, YK | 1 |
| Baliga, VP | 1 |
| Bollmall, C | 1 |
| Frishman, WH | 1 |
| Brobyn, R | 1 |
| Brown, RD | 1 |
| Johnson, BF | 1 |
| Reeves, RL | 1 |
| Wombolt, DG | 1 |
| Bremner, AD | 1 |
| Fell, PJ | 1 |
| Hosie, J | 1 |
| James, IG | 1 |
| Saul, PA | 1 |
| Taylor, SH | 1 |
| Kokot, F | 1 |
| Witkowicz, J | 1 |
| Kokot, M | 1 |
| Rychlik, G | 1 |
| Raszewska, J | 1 |
| Corea, L | 1 |
| Cardoni, O | 1 |
| Fogari, R | 1 |
| Innocenti, P | 1 |
| Porcellati, C | 1 |
| Provvidenza, M | 1 |
| Meilenbrock, S | 1 |
| Sullivan, J | 1 |
| Bodin, F | 1 |
| Schaefer, RM | 1 |
| Aldons, PM | 1 |
| Burgess, ED | 1 |
| Tilvis, R | 1 |
| Girerd, X | 1 |
| Singh, GP | 1 |
| Rehn, L | 1 |
| Morgan, TO | 1 |
| Zimmermann, T | 1 |
| Laufen, H | 1 |
| Yeates, R | 1 |
| Scharpf, F | 1 |
| Riedel, KD | 1 |
| Schumacher, T | 1 |
| Hall, R | 1 |
| Chong, C | 1 |
| Mroczek, WJ | 1 |
| Burris, JF | 1 |
| Klein, J | 1 |
| Varrone, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by[NCT02738632] | Phase 3 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Completed | ||
| [NCT01518998] | Phase 2 | 420 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension[NCT00739596] | Phase 4 | 332 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To compare the percentage of patients achieving BP control (<140/90 mm Hg) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: 8 weeks
| Intervention | Cumulative percentage of participants (Number) |
|---|---|
| Aliskiren HCTZ | 63.6 |
| Amlodipine | 62.3 |
To compare the percentage of responders after 8 weeks of treatment with an aliskiren HCTZ based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension: [ Responders were defined as patients with MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg at 1st response. A response was counted when a patient first achieved MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg.] (NCT00739596)
Timeframe: 8 weeks
| Intervention | Cumulative percentage of responders (Number) |
|---|---|
| Aliskiren HCTZ | 84.6 |
| Amlodipine | 90.7 |
To assess the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from Baseline to Week 8 | |
| Aliskiren HCTZ | 96.0 | 86.0 | -10.0 |
| Amlodipine | 95.0 | 84.0 | -11.0 |
To compare the change from baseline in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from Baseline to Week 8 | |
| Aliskiren HCTZ | 72.2 | 52.7 | -19.4 |
| Amlodipine | 73.1 | 55.1 | -18.0 |
To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline to Week 8 | |
| Aliskiren HCTZ | 168.2 | 138.8 | -29.4 |
| Amlodipine | 168.1 | 139.1 | -29.0 |
2 reviews available for amlodipine and Headache
| Article | Year |
|---|---|
Cardiac Memory: A Case Report and Review of the Literature.
Topics: Aged; Amlodipine; Arrhythmias, Cardiac; Aspirin; Bundle-Branch Block; Chest Pain; Electrocardiograph | 2019 |
Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Edema; Headache; Humans; Hypertension | 2019 |
20 trials available for amlodipine and Headache
| Article | Year |
|---|---|
Efficacy and Tolerability of Telmisartan/Amlodipine + Hydrochlorothiazide Versus Telmisartan/Amlodipine Combination Therapy for Essential Hypertension Uncontrolled With Telmisartan/Amlodipine: The Phase III, Multicenter, Randomized, Double-blind TAHYTI St
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dizzine | 2018 |
A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind M | 2015 |
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
Topics: Adult; Amides; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Brach | 2011 |
Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension.
Topics: Adult; Amides; Amlodipine; Black or African American; Blood Pressure; Blood Pressure Monitoring, Amb | 2011 |
Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzopyrans; Blood Pressure; Double-Bl | 2002 |
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channe | 2003 |
Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.
Topics: Adipates; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Capsules; Double-Blind M | 2005 |
Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet.
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Area Under Curve; Atorvastatin | 2006 |
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Double-Blind Method; | 2007 |
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Topics: Adamantane; Administration, Oral; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiot | 2008 |
Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stag
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo | 2007 |
Amlodipine versus atenolol in essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Double-Blind Method; Drug Administrat | 1994 |
Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard.
Topics: Adult; Aged; Amlodipine; Delayed-Action Preparations; Dizziness; Double-Blind Method; Edema; Female; | 1993 |
-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Dizziness; Drug Administration Schedule; Edema; Fe | 1995 |
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 1996 |
Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group.
Topics: Aged; Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dizziness; Double-Blind Meth | 1998 |
The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times.
Topics: Adult; Amlodipine; Area Under Curve; Biological Availability; Calcium Channel Blockers; Cross-Over S | 1999 |
A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the management of elderly patients with stable angina.
Topics: Aged; Aged, 80 and over; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Dela | 2001 |
A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Calcium Channel B | 1991 |
A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Edema; Female; Headache; Human | 1991 |
8 other studies available for amlodipine and Headache
| Article | Year |
|---|---|
Multiple Cerebral Aneurysms Treated by Microsurgical and Endovascular Technique.
Topics: Amlodipine; Aneurysm, Ruptured; Embolization, Therapeutic; Endovascular Procedures; Female; Headache | 2022 |
The hypertensive child.
Topics: Abdominal Pain; Adrenocorticotropic Hormone; Aldosterone; Amlodipine; Antihypertensive Agents; Catec | 2019 |
Detection of significant left renal artery stenosis caused by fibromuscular dysplasia with selective angiography.
Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Computed Tomography Angiography; Drug Com | 2020 |
A Big Headache: An Unusual Case of Hypertensive Urgency in an Adolescent.
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Aorta, Abdominal; Aortic Valve Stenosis; Computed T | 2021 |
Nephrotic range proteinuria and metabolic alkalosis in Takayasu arteritis.
Topics: Adolescent; Alkalosis; Amlodipine; Antihypertensive Agents; Female; Glomerulosclerosis, Focal Segmen | 2019 |
Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Drug Combinations; Drug Sub | 2015 |
Does this patient have hypertensive encephalopathy?
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tom | 2016 |
A 36-year-old man with paresthesias and a headache.
Topics: Adult; Amlodipine; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Guanine; Headache; He | 2008 |